BioInvent Presents New Clinical and Preclinical Data of BI-1206 at ASH Annual Meeting
Shots:
- The data includes P-l/lla study involves assessing BI-1206 + rituximab in patients with FL- MZL and MCL who have r/r to rituximab. The study demonstrated at BI-1206 is generating the first signs of clinical response in patients
- The company also presents results from two preclinical studies. The preclinical data further reinforce the efficacy and tolerability profile of BI-1206
- BI-1206 has a novel mode-of-action- acts by blocking the single inhibitory Ab checkpoint receptor FcγRIIB to unlock anti-cancer immunity in both liquid and solid tumors. The therapy is currently being evaluated in P-I/II study in combination with Keytruda & in P-I/IIa study in combination with MabThera (rituximab) for NHL
Ref: PRNewswire | Image: Contract Pharma
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com